Skip to main content
Premium Trial:

Request an Annual Quote

OGT Inks Deal with CCMC to Build Cancer Microarray

NEW YORK (GenomeWeb News) – Oxford Gene Technology said today it signed a license agreement with the Cancer Cytogenomics Microarray Consortium to create a whole genome, cancer-specific microarray.

The technology will incorporate probes for more than 500 cancer genes and 130 cancer-associated genomic regions from CCMC's design for hematological and solid tumors, OGT said. By accurately identifying DNA copy number changes and the loss of heterozygosity associated with different cancer types, OGT hopes to improve cancer research through the agreement.

Financial and other terms of the deal were not disclosed.

"The use of microarray technology will substantially improve the facility of cytogenetics research laboratories to identify cancer," M. Anwar Iqbal, president of CCMC, said in a statement. "The CCMC board appreciates the efforts of companies such as OGT to making the CCMC cancer array design available to the cytogenetics research community worldwide."

Formed in 2009, CCMC promotes communication and collaboration among cancer cytogenomic laboratories.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.